Cargando…
Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis
BACKGROUND: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has been used to treat patients with diffuse large B-cell lymphoma (DLBCL) under National Health Insurance (NHI) scheme in Indonesia. This study aims to estimate its cost-effectiveness and budget impact. M...
Autores principales: | Putri, Septiara, Setiawan, Ery, Saldi, Siti Rizny F., Khoe, Levina Chandra, Sari, Euis Ratna, Megraini, Amila, Nadjib, Mardiati, Sastroasmoro, Sudigdo, Armansyah, Armansyah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040215/ https://www.ncbi.nlm.nih.gov/pubmed/35468783 http://dx.doi.org/10.1186/s12913-022-07956-w |
Ejemplares similares
-
Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting
por: Putri, Septiara, et al.
Publicado: (2023) -
Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia
por: Kristin, Erna, et al.
Publicado: (2021) -
Cost and affordability of scaling up tuberculosis diagnosis using Xpert MTB/RIF testing in West Java, Indonesia
por: Nadjib, Mardiati, et al.
Publicado: (2022) -
Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia
por: Afiatin,, et al.
Publicado: (2017) -
Economic burden of dengue in Indonesia
por: Nadjib, Mardiati, et al.
Publicado: (2019)